FASN Antibodies

Structure of FASN

FASN is a large multifunctional enzyme-protein complex with a molecular weight of approximately 270-273 kDa. Its molecular weight varies slightly among different species, mainly depending on the composition of subunits and post-translational modifications.

FASN is composed of approximately 2,500 amino acids, forming a dimer structure. Each monomer contains seven catalytic domains such as ketoacyl synthase (KS), acyl carrier protein (ACP), and alkenyl reductase (ER), all of which jointly participate in the stepwise synthesis of fatty acids. Its tertiary structure presents a highly ordered conformation, mediating substrate transfer through thioester bonds, while NADPH provides reducing force to drive the reaction. The active center of FASN has hydrophobic pockets that can accommodate the continuously elongated fatty acid chain. Its phosphorylation modification sites (such as Ser2021) can regulate enzyme activity and affect metabolic rates.

Fig. 1 Sequences of FASN phospho-degron mutant constructs.¹

Key structural properties of FASN:

• Multi-domain complex
• Acyl carrier protein (ACP) core
• NADPH binding site
• Substrate channel
• Dimerization interface

Functions of FASN

The core function of FASN (Fatty Acid synthase) is to catalyze the synthesis of long-chain fatty acids, and it also plays multiple roles in metabolic regulation and disease occurrence.

The catalytic mechanism of FASN presents a linear and progressive characteristic. Unlike the stepwise reactions of single-function enzymes, its seven domains work together to complete repetitive steps such as condensation, reduction, and dehydration until the thiesterase (TE) domain finally releases palmitic acid. This "metabolic pipeline" model significantly enhances synthetic efficiency, but it also makes it an important target for the treatment of metabolic diseases.

Applications of FASN and FASN Antibody in Literature

1. Wei, Wenxia, et al. "FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth." Signal Transduction and Targeted Therapy 8.1 (2023): 187. https://doi.org/10.1038/s41392-023-01405-8

The article indicates that FBXW7β inhibits lipid synthesis in colorectal cancer (CRC) by ubiquitinating and degrading FASN, while the oncogenic protein CSN6 binds to FASN and antagonizes FBXW7β, promoting FASN stability and lipid production. The EGF-CSN6-FASN axis drives the progression of CRC. The combined use of oristat and cetuximab can inhibit the growth of CRC tumors with high expression of CSN6/FASN.

2. Du, Qiqiao, et al. "FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis." Cell death & disease 13.5 (2022): 488.https://doi.org/10.1038/s41419-022-04926-2

The article indicates that FASN is highly expressed in cervical cancer (CC) and promotes lymph node metastasis (LNM). It enhances invasion by regulating cholesterol reprogramming to activate the c-Src/AKT/FAK signaling pathway and secretes PDGF-AA/IGFBP3 to induce lymphangiogenesis. Inhibition of FASN can significantly reduce LNM, suggesting its potential as a prognostic marker and therapeutic target.

3. Liu, Bangdong, et al. "Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma." Leukemia 38.2 (2024): 351-364.https://doi.org/10.1038/s41375-023-02130-5

The article indicates that palmitoyltransferase ZDHHC21 hinders the progression of diffuse large B-cell lymphoma (DLBCL) by mediating the palmitoylation of FASN (Cys1317 site), reducing its stability and inhibiting fatty acid synthesis. The FDA-approved drug, senoside C, can stabilize ZDHHC21 and down-regulate FASN. Targeting the ZDHHC21/FASN axis has therapeutic potential.

4. Ye, Mujie, et al. "FABP5 suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN expression." International Journal of Biological Sciences 19.10 (2023): 3115.https://doi.org/10.7150/ijbs.85285

The article indicates that FABP5 is lowly expressed in colorectal cancer. It promotes the ubiquitination and degradation of FASN by binding to it, reduces lipid accumulation and inhibits the mTOR pathway, thereby suppressing tumor growth. ALKBH5 upregulates FABP5 through a non-M6A mechanism, revealing the tumor suppressor effect of the ALKBH5/FABP5/FASN/mTOR axis in CRC.

5. Liang, Junxian, et al. "PITPNC1 Suppress CD8+ T cell immune function and promote radioresistance in rectal cancer by modulating FASN/CD155." Journal of Translational Medicine 22.1 (2024): 117. https://doi.org/10.1186/s12967-024-04931-3

Research has found that PITPNC1 promotes the expression of CD155 by up-regulating FASN, inhibits the function of CD8+T cells, and leads to radiotherapy resistance in rectal cancer. Targeting the PITPNC1/FASN/CD155 pathway can reverse immunosuppression and enhance radiosensitivity.

Creative Biolabs: FASN Antibodies for Research

Creative Biolabs specializes in the production of high-quality FASN antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom FASN Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our FASN antibodies, custom preparations, or technical support, contact us at email.